EGFR and non-small cell lung carcinoma: Another study explored the sensitivity of EGFR variants to different approved inhibitors by implementing a cytotoxicity screen in the NSCLC cell line PC-9 depleted of endogenous EGFR and transduced with a lentiviral mutant library, and numerous common but also drug-selective variants were reported [77].